Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.263
+0.004 (1.55%)
At close: Nov 4, 2024, 4:00 PM
0.264
+0.001 (0.27%)
After-hours: Nov 4, 2024, 7:55 PM EST
Lyra Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 1.82 | 1.56 | 1.36 | 0.29 | - | - | |
| Revenue Growth (YoY) | 47.01% | 14.31% | 378.25% | - | - | - | |
| Cost of Revenue | 56.14 | 48.03 | 38.8 | 29.69 | 12.52 | - | |
| Gross Profit | -54.32 | -46.47 | -37.43 | -29.41 | -12.52 | - | |
| Selling, General & Admin | 20.32 | 19.06 | 17.56 | 14.21 | 9.69 | 4.49 | |
| Research & Development | - | - | - | - | - | 12.03 | |
| Operating Expenses | 20.32 | 19.06 | 17.56 | 14.21 | 9.69 | 16.52 | |
| Operating Income | -74.63 | -65.53 | -54.99 | -43.62 | -22.21 | -16.52 | |
| Interest & Investment Income | 4.47 | 4.5 | 1.04 | 0.1 | 0.08 | 0.21 | |
| EBT Excluding Unusual Items | -70.16 | -61.03 | -53.95 | -43.51 | -22.13 | -16.31 | |
| Asset Writedown | -24.72 | -1.59 | -1.32 | - | - | - | |
| Pretax Income | -101.33 | -62.62 | -55.27 | -43.51 | -22.13 | -16.31 | |
| Income Tax Expense | 0.06 | 0.06 | 0.01 | - | - | - | |
| Net Income | -101.39 | -62.68 | -55.28 | -43.51 | -22.13 | -16.31 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.12 | 0.31 | |
| Net Income to Common | -101.39 | -62.68 | -55.28 | -43.51 | -22.24 | -16.62 | |
| Shares Outstanding (Basic) | 62 | 50 | 30 | 13 | 9 | 0 | |
| Shares Outstanding (Diluted) | 62 | 50 | 30 | 13 | 9 | 0 | |
| Shares Change (YoY) | 60.70% | 64.72% | 132.83% | 51.17% | 4150.62% | 21.66% | |
| EPS (Basic) | -1.63 | -1.26 | -1.83 | -3.35 | -2.59 | -82.23 | |
| EPS (Diluted) | -1.64 | -1.26 | -1.83 | -3.35 | -2.59 | -82.23 | |
| Free Cash Flow | -78.88 | -64.35 | -43.55 | -29.21 | -22.92 | -13.97 | |
| Free Cash Flow Per Share | -1.27 | -1.29 | -1.44 | -2.25 | -2.67 | -69.10 | |
| Operating Margin | -4100.71% | -4205.91% | -4034.48% | -15303.51% | - | - | |
| Profit Margin | -5570.88% | -4023.11% | -4055.61% | -15267.72% | - | - | |
| Free Cash Flow Margin | -4334.29% | -4130.36% | -3195.08% | -10247.37% | - | - | |
| EBITDA | -74.34 | -65.25 | -53.92 | -42.61 | -22.11 | -16.49 | |
| D&A For EBITDA | 0.3 | 0.28 | 1.07 | 1 | 0.1 | 0.03 | |
| EBIT | -74.63 | -65.53 | -54.99 | -43.62 | -22.21 | -16.52 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.